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Summary Staging and surgical as well as post-operative treatment of primary Fallopian tube carcinoma
(FTC) followed the lines established for primary ovarian cancer (OC). In a nationwide retrospective analysis
we were able to find a distinct difference between these two tumours. A total of 262 patients, 68 with FTC and
194 with OC, in stage I and II were included into this study. A univariate as well as a multivariate analysis for
survival was performed, including factors such as age, histological type, grading and surgical and adjuvant
treatment. A significantly poorer outcome (P = 0.0002) for FTC patients with a 5-year survival of 50.8%
compared with 77.5% for OC patients was observed. This finding was persistent and independent of any
investigated factor, in univariate as well as multivariate analyses. Therefore, we feel that a more aggressive
therapeutic approach to the treatment of FTC even in early stages can be recommended. On the other hand,
the retrospective character of our study has to be taken into account.
Primary carcinoma of the Fallopian tube (FTC) ranks among
the rarest of gynaecological malignancies, with a prevalence
reported to be 0.15-1.8% compared with 9.4-15.8% for
epithelial ovarian cancer (OC) (Hanton et al., 1966; Dodson
et al., 1970; Engeler et al., 1981; Bohme et al., 1992). The
average annual incidence of FTC is reported to be 2.9 per
million women per year (Pfeiffer, 1989).
Since both tumours have their origin in the Mullerian duct,
OC and FTC are considered to be closely related (Frick,
1978). Thus, FIGO staging (until September 1991), surgical
treatment and post-operative adjuvant therapy of FTC fol-
lowed the lines established for OC (Hu et al., 1950; Behr et
al., 1990; Morris et al., 1990; Pakisch et al., 1990).
In most cases 'primary carcinoma of the Fallopian tube' is
diagnosed intraoperatively or even as late as in the
pathologist's post-operative histological examination;
preoperatively, the tumour is mostly diagnosed as 'ovarian
carcinoma' or 'malignant process in the adnexa' (Jones,
1965). The present retrospective study analyses data over a
10-year period (First and Second Multicenter Studies on
Ovarian Carcinoma in Austria and First Multicenter Study
on Carcinoma of the Fallopian Tube in Austria), and aims at
evaluating the prognostic characteristics of the two
diseases.
Patients
During the period 1980 to 1990, patients operated on for
epithelial ovarian carcinoma or primary carcinoma of the
Fallopian tube in stage I and II were entered into this
retrospective study.
Data on patients with Fallopian tube carcinoma were
taken from a retrospective, multicentre analysis, including 23
gynaecological departments, and have been recently reported.
(Rosen et al., 1993).
Data for ovarian carcinoma were received from the
University of Vienna (1st and 2nd Departments of Obstetrics
and Gynecology) and were collected and analysed by the
second author (P.S.) at the University of Vienna, Austria.
They involved patients with OC who had been entered into
two multicentre studies, from all over Austria.
FTC as well as OC patients were followed until the control
date, October 1992.
Patients with metastatic tumours, with a history of other
malignancies and with borderline tumours were excluded
from this study.
For the staging of Fallopian tube carcinoma a new FIGO
classification, founded in Singapore, 1991, was used, whereas
for ovarian carcinoma the FIGO classification was app-
lied.
Table I Patient characteristics: 68 with Fallopian tube and 194 with
ovarian carcinoma
Fallopian tube Ovary P-value
FIGO
IA 31 (45.6%) 83 (42.9%) NS
IB 9 (13.2%) 28 (14.4%) NS
IC 11 (16.2%) 51 (26.2%) NS
IIA 8 (11.8%) 19 (9.8%) NS
IIB 7 (10.3%) 8 (4.1%) NS
IIC 2 (2.9%) 5 (2.6%) NS
Grading
GI 20 (29.4%) 83 (42.8%) NS
G2 26 (38.2%) 65 (33.5%) NS
G3 22 (32.4%) 46 (23.7%) NS
Histology
Serous 14 (20.9%) 109 (56.5%)
Mucinous 3 (4.5%) 22 (11.4%)
Papillary 34 (50.7%)
Solid 9 (13.4%)
Medullary 7 (10.4%)
Endometrioid - 29 (15.0%)
Clear cell - 6 (3.1%)
Undifferentiated - 9 (4.7%)
Other - 18 (9.3%)
Unknown I
Operation
BSO + TAH + 22 (32.4%) 96 (49.5%) NS
nodes +
omentectomy
BSO + TAH 42 (61.8%) 75 (38.7%) 0.03
USO 4 (5.9%) 23 (11.9%) NS
Adjuvant
Radiation 31 (45.6%) 65 (33.5%) NS
Chemotherapy 21 (30.9%) 59 (30.4%) NS
No therapy 16 (23.5%) 70 (36.1%) NS
Abbreviations: BSO, bilateral salpingo-oophorectomy; TAH, total
abdominal hysterectomy; USO, unilateral salpingo-oophorectomy.
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A total of 68 patients with primary cancer of the Fallopian
tube (FTC) in FIGO stage I and II were included into this
study and were compared with 194 patients with ovarian
carcinoma (OC) in the same stages (Table I). The mean age
of Fallopian tube patients was 60.4 years. The mean age of
ovarian carcinoma patients was 56.1 years.
A total of 51 (73.6%) FTC patients were in stage I,
compared with 162 (83.5%) OC patients. For stage II the
figures were 17 (26.4%) and 32 (16.5%) for FTC and OC
respectively (P = NS).
Histological evaluation and grading for FTC followed the
criteria of Hu et al. (1950). The histological evaluation of the
epithelial ovarian cancer was by WHO criteria (Serov et al.,
1973). Histological grading was GI for well-differentiated
and G3 for undifferentiated ovarian carcinomas and followed
the criteria of Day et al. (1975). Borderline tumours (GO)
were excluded from this study.
The participating departments provided the study centre
with histological specimens, which were evaluated by an
independent pathologist (A.R.) for grading and histological
type.
Total abdominal hysterectomy (TAH) with bilateral
salpingo-oophorectomy (BSO) and additional infracolic
resection of the omentum together with or without lym-
phadenectomy was achieved in 22 (32.4%) patients in the
FTC group and 96 (49.5%) patients in the OC group
(P= NS).
Post-operative radiotherapy was performed in 31 (45.6%)
women with FTC and 65 (33.5%) women with OC using
whole-abdominal irradiation with open-field techniques and
total dosage of 45-55 Gy. The source of radiation was
cobalt-60 in all patients and was applied within 6 weeks after
surgery.
Table II Impact of prognostic factors on survival (Mantel test)
Five-year 75% quantile P-value
n survival (%) (months) univariate
Grading
GI 20a 66 29.2 0.01
83b 88 Not reached
G2 + 48a 49 26.2 0.01
G3 Illb 67 45.7
Surgical 22a 52 29.2 0.08
procedurec 96b 78 Not reached
Adjuvant
therapy 16a 72 34.1 0.1
None 70b 84 Not reached
Radiation 31a 48 25.6 0.04
65b 74 48.5
Chemotherapy 21a 52 19.4 0.01
59b 70 47.7
aFallopian tube cancer. bOvarian cancer. CBSO + TAH + omen-
tectomy with or without lymphadenectomy.
Twenty-one women (30.9%) with FTC underwent chemo-
therapy compared with 59 (30.4%) with OC. The post-
operative chemotherapy regimen varied from department to
department and changed between the early 1980s and 1990.
But in most of the reported cases a cisplatin-containing
polychemotherapy regimen was administered with a concen-
tration of 50 mg m2 cisplatin until 1984 and an increasing
dosage up to 100 mg m-2 until now.
Sixteen (23.5%) patients with FTC and 70 (36.1%)
patients with OC did not receive any adjuvant therapy
because their tumours were in stage IA and histological grade
was GI (P =NS).
Statistical methods
Results expressed as percentages were subjected to a chi-
square test. Survival curves were obtained by the Kaplan-
Meier method, and median survival was compared by the
Mantel-Cox log-rank test (Kaplan & Meier, 1958; Cox,
1972; Mantel, 1986).
Patients who died from any cause other than the primary
disease were censored. Five patients with FTC died for
reasons other than the primary disease compared with 12
patients with OC. Survival was regarded as the period from
first treatment for OC or FTC until the time of death due to
this disease or until the control date. Values of P<0.05 were
considered to be statistically significant.
Cox proportional hazards regression (Cox, 1972), as imple-
mented by the program BMDP 2L (Dixon et al., 1990), was
used to analyse the role of prognostic factors in survival,
both in a marginal, unadjusted and in a partial, adjusted
sense. In this analysis the prognostic strength of a factor is
described by estimates of the relative risk, and by the corre-
sponding 95% confidence interval for the relative risk. Two-
sided P-values permit a judgement as to whether the relative
risk differs significantly from 1. Wherever feasible, hazard
plots were performed to assess the appropriateness of the
proportional hazards assumption that underlies the Cox
regression model. Log-likelihood ratio tests were used to
determine the significance of factor combinations.
Survival
Survival data, describing the impact of various prognostic
factors, are given in Table II. The results of the Cox analysis
are shown in Table III. The fit of the model was checked by
considering interaction and polynominal terms in a stepwise
modelling process. Based on these analyses it can be con-
cluded that a main-effects model suitably summarises the
survival experiences of the patients. The results show that the
presence of FTC was the most important adverse prognostic
factor, the next being a higher degree of dedifferentiation
(G2 + G3). Furthemore, age had a significant influence on
survival (Table III).
Table III Results of analysis of survival by Cox regression multiple regression
95% confidence
Prognostic factor Relative risk interval P-value
Tube vs ovarian carcinoma 2.19:1 1.256-3.814 0.0002
Grade: G2 + G3 vs GI
Age (continuous variable) 2.63:1 1.310-5.279 <0.01
Therapya: 2 vs 1.03/1 1.002-1.051 0.0344
1 vs 0
Operationb: USO and 1.43:1.90:1 0.674-3.031/ 0.2398
TAH + BSO vs089407
TAH + BSO + omentum ±nodes 0.93:1 0.530-1.617 0.7854
ao, no therapy; 1, irradiation therapy; 2, chemotherapy. bUSO, unilateral salpingo-
oophorectomy; BSO, bilateral salpingo-oophorectomy; TAH, total abdominal
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Discussion
Carcinoma of the Fallopian tube and of the ovary share
similar histological features and arise from continuous struc-
tures. Because of this and the limited experience with this
disease, FTC is often managed along similar lines to OC
(Gurney et al., 1990; Morris et al., 1990).
FTC spreads within the abdominal cavity in a manner
similar to OC, first contiguously by invasion of adjacent
organs (Erez et al., 1967; Benedet et al., 1977; Henderson et
al., 1977), second by lymphatic pathways, and third by
haematogenous spread (Engstrom, 1957; Benedet et al., 1977;
Yoonessi, 1979).
Symptoms of FTC are predominantly non-specific (uterine
bleeding, pelvic and/or abdominal pain, abnormal vaginal
discharge, abdominal distension and ascites with or without
intestinal symptoms, and pelvic mass). This might explain the
low rate (2%) of preoperative diagnosis (Jones, 1965;
Yoonessi, 1979). FTC closely resembles OC with one striking
difference, i.e. that in FTC abdominal pain is a frequent and
early complaint (Roberts & Lifshitz, 1982).
It seems that patients are able to seek medical attention
earlier because FTC tends to present at an earlier stage than
OC (Rosen et al., 1993).
Gurney et al. (1990) emphasises the same biological re-
sponse of FTC and OC to therapy. We cannot share this
view because of the evidently worse prognosis for FTC in
stage I and II despite the same treatment and the earlier
diagnosis of FTC (Gurney et al., 1990; Rosen et al., 1993).
(Figure 1).
On the whole, FTC patients have a significantly worse
outcome irrespective of their histological type or grading,
though within the FTC groups GI tumours proved to have a
better prognosis than G2 and G3 tumours. The difference in
survival caused by the presence of FTC is persistent in
univariate as well as in multivariate analysis and has an
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Figure 1 Survival probability in stage I and II ovarian vs Fal-
lopian tube cancer.
influence independent of any applied treatment modality
(Tables II, III and Figure 1).
Unlike OC, there are no specific therapeutic guidelines
available for FTC. The literature offers only retrospective
studies and reports on series too small to allow definitive
conclusions (Phelps & Chapman, 1974; Morris et al., 1990;
Pakisch et al., 1990; Barakat et al., 1991).
Our study too, though based on a homogeneous patient
series of 68 FTC cases (Rosen et al., 1993), is retrospective
and cannot provide conclusive guidelines for therapy. Yet,
we feel that some recommendations can be given. Post-
operative treatment of FTC, either chemo- or radiotherapy,
which hitherto followed the example of OC, should be
actively pursued, and we think that the decision to apply
adjuvant treatment in FTC patients should be made even in
earlier stages.
Patients with FIGO stage IA, in particular, should receive
adjuvant treatment as well, irrespective of their histological
grading, and in contrast to OC, so that a benefit from early
diagnosis might be achieved. However, to determine defini-
tive guidelines for treatment of FTC multicentric, prospective
(probably international) trials will be mandatory.
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